MARKET

MDT

MDT

Medtronic
NYSE

Real-time Quotes | Nasdaq Last Sale

106.26
+2.45
+2.36%
After Hours: 106.86 +0.6 +0.56% 18:06 05/17 EDT
OPEN
105.27
PREV CLOSE
103.81
HIGH
106.33
LOW
104.99
VOLUME
3.17M
TURNOVER
0
52 WEEK HIGH
135.89
52 WEEK LOW
98.38
MARKET CAP
142.55B
P/E (TTM)
29.25
1D
5D
1M
3M
1Y
5Y
4 Analysts Have This to Say About Medtronic
Within the last quarter, Medtronic (NYSE:MDT) has observed the following analyst ratings:
Benzinga · 5h ago
EuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation (RDN) system on achieving target blood pressure level ra...
CNW Group · 11h ago
Here's What To Make Of Medtronic's (NYSE:MDT) Decelerating Rates Of Return
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
Simply Wall St. · 1d ago
Dalio's Bridgewater invests in Berkshire Hathaway, exits Tesla in Q1
Ray Dalio's Bridgewater Associates took a new stake in Berkshire Hathaway (BRK.B), one of the U.S.'s largest insurance, investment, manufacturing and energy companies during Q1 2022. It also invested in
Seekingalpha · 1d ago
Medtronic's (MDT) Onyx Frontier DES Receives FDA Approval
Medtronic's (MDT) Onyx Frontier DES is utilized to treat patients with CAD.
Zacks · 1d ago
Here's how CEO pay for Minnesota's biggest public companies compares to median employees compensation
Total CEO pay for Minnesota's 25 largest public companies increased between 2020 and 2021, and most companies' CEO compensation is growing faster than their median employees' pay.
American City Business Journals · 2d ago
Medtronic gets FDA approval for Onyx Frontier drug-eluting stent for coronary artery disease
Medtronic (NYSE:MDT) said it received U.S. Food and Drug Administration (FDA) approval for its Onyx Frontier drug-eluting stent (DES). The medical device maker added that the Onyx Frontier DES is
Seekingalpha · 4d ago
Medtronic Reports Received FDA Approval For Onyx Frontier Drug-Eluting Stent
The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent DUBLIN, May 13, 2022
Benzinga · 4d ago
More
No Data
Learn about the latest financial forecast of MDT. Analyze the recent business situations of Medtronic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 29 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

24.14%Strong Buy
44.83%Buy
31.03%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MDT stock price target is 124.18 with a high estimate of 149.00 and a low estimate of 105.00.
High149.00
Average124.18
Low105.00
Current 106.26
EPS
Actual
Estimate
0.390.791.181.57
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 2.53K
Institutional Holdings: 1.17B
% Owned: 87.32%
Shares Outstanding: 1.34B
TypeInstitutionsShares
Increased
848
58.70M
New
219
5.99M
Decreased
722
57.30M
Sold Out
193
6.90M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.93%
Healthcare Equipment & Supplies
+2.38%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Geoffrey Martha
Chief Financial Officer/Executive Vice President
Karen Parkhill
Chief Human Resource Officer/Senior Vice President
Carol Surface
Executive Vice President
Robert ten Hoedt
Executive Vice President
John Liddicoat
Executive Vice President
Sean Salmon
Executive Vice President
Brett Wall
Executive Vice President
Robert White
Chief Accounting Officer/Controller
Jennifer Kirk
Lead Director/Independent Director
Scott Donnelly
Independent Director
Richard Anderson
Independent Director
Craig Arnold
Independent Director
Andrea Goldsmith
Independent Director
Randall Hogan
Independent Director
Kevin Lofton
Independent Director
Elizabeth Nabel
Independent Director
Denise O'Leary
Independent Director
Kendall Powell
No Data
No Data
About MDT
Medtronic Public Limited Company is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients. The Company has four operating and reportable segments that primarily develop, manufacture, distribute, and sell device-based medical therapies and services: the Cardiovascular Portfolio, the Medical Surgical Portfolio, the Neuroscience Portfolio, and the Diabetes Operating Unit. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions.

Webull offers kinds of Medtronic PLC stock information, including NYSE:MDT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDT stock methods without spending real money on the virtual paper trading platform.